Edition:
United States

Alnylam Pharmaceuticals Inc (ALNY.O)

ALNY.O on Nasdaq

65.80USD
26 May 2017
Change (% chg)

$-3.70 (-5.32%)
Prev Close
$69.50
Open
$69.27
Day's High
$70.49
Day's Low
$65.50
Volume
1,356,852
Avg. Vol
1,033,544
52-wk High
$80.11
52-wk Low
$31.38

Select another date:

Wed, May 24 2017

BRIEF-Alnylam Pharmaceuticals prices public offering of common stock

* Alnylam Pharmaceuticals prices public offering of common stock

BRIEF-Alnylam Pharmaceuticals reports proposed public offering of common stock

* Alnylam Pharmaceuticals announces proposed public offering of common stock

BRIEF-Alnylam Pharmaceuticals appoints Manmeet Soni as chief financial officer

* Alnylam Pharmaceuticals Inc - appointment of Manmeet S. Soni as chief financial officer Source text for Eikon: Further company coverage:

BRIEF-Alnylam Pharmaceuticals files for potential mixed shelf offering

* Files for potential mixed shelf offering; size not disclosed Source text: (bit.ly/2pNQPaG) Further company coverage:

BRIEF-Alnylam Pharmaceuticals reports Q1 loss per share of $1.25 including items

* Alnylam pharmaceuticals reports first quarter 2017 financial results and highlights recent period activity

BRIEF-ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN

* ALNYLAM REPORTS FINAL 24-MONTH RESULTS FROM PHASE 2 OPEN-LABEL EXTENSION STUDY OF PATISIRAN, AN INVESTIGATIONAL RNAI THERAPEUTIC IN DEVELOPMENT FOR THE TREATMENT OF HEREDITARY ATTR (HATTR) AMYLOIDOSIS

BRIEF-Medicines Co, Alnylam Pharma announce agreement with FDA on phase III clinical program for inclisiran

* The medicines company and alnylam pharmaceuticals announce agreement with fda on phase iii clinical program for inclisiran

BRIEF-Invitae Corp announces a program in partnership with Alnylam Pharmaceuticals

* Announced a program in partnership with Alnylam Pharmaceuticals to provide genetic testing for hereditary ATTR (HATTR) amyloidosis Source text for Eikon: Further company coverage:

BRIEF-Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran

* Alnylam receives European Medicines Agency prime designation for accelerated assessment of givosiran, an investigational rnai therapeutic for the treatment of acute hepatic porphyrias

BRIEF-Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity

* Alnylam Pharmaceuticals reports fourth quarter and full year 2016 financial results and highlights recent period activity

Select another date:

More From Around the Web